



February 20, 2019

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

**The National Stock Exchange of India Limited**  
Exchange Plaza , Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Sirs,

**Sub: Press Release**

Please find attached press release issued by the Company titled:

**“Strides receives USFDA approval for  
Ethosuximide Softgel Capsules”**

Thanks and Regards

For **Strides Pharma Science Limited**

A handwritten signature in blue ink that reads 'Manjula R.'.

**Manjula Ramamurthy**  
Company Secretary



**Strides Pharma Science Limited**

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

**Corp Off:** Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

**Regd Off:** 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com



## Press Release

February 20, 2019

---

### **Strides receives USFDA approval for Ethosuximide Softgel Capsules**

**Softgel franchise now comprises of 10 approved products in the US  
To be launched immediately by Strides Pharma Inc. in the US market**

---

**Bangalore, 20 February 2019** Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for ***Ethosuximide Softgel Capsules USP, 250 mg*** from the United States Food & Drug Administration (USFDA). The product was approved in the first review cycle by the USFDA in **less than 10 months of filing under the GDUFA II regime**. The product is a generic version of Zarontin Capsules, 250 mg, of Pfizer Inc.

Strides specializes in softgel domain and is a global leader in the Rx space. Strides now has a large portfolio of softgel products which now comprises of 10 approved products for the US markets along with a strong product pipeline. Ethosuximide Softgel Capsules is part of Strides niche and small volume product portfolio with limited competition in the US market. According to IQVIA MAT data, the US market for Ethosuximide Softgel Capsules USP, 250 mg is approximately US\$ 10 Mn. As part of its portfolio maximization strategy, Strides will also commercialize the product in other geographies leveraging its vast footprint in other regulated markets.

The product will be manufactured at flagship facility in Bangalore and will be marketed by Strides Pharma Inc. in the US market.

The company has 86 cumulative ANDA filings with USFDA of which 57 ANDAs have been approved including 13 approvals received in FY 19.

#### **About Ethosuximide Softgel Capsule**

Ethosuximide Softgel capsule is an anti-epileptic medication to control brief, sudden loss of consciousness and uncontrolled jerking movements in children and adults.

#### **About Strides**

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two sites), Pondicherry and Chennai, Singapore, Italy- Milan, and Kenya- Nairobi. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at [www.strides.com](http://www.strides.com)

**For further information, please contact:**

**Strides**

Badree Komandur,  
Executive Director - Finance  
+91 80 6784 0747

**Investor Relations:**

Kannan. N: +91 98450 54745  
Vikesh Kumar: +91 80 6784 0827  
Sandeep Baid : +91 80 6784 0791  
Email: [Sandeep.baid@strides.com](mailto:Sandeep.baid@strides.com)

**Strides Pharma Science Limited**

(Formerly Strides Shasun Limited)  
CIN : L24230MH1990PLC057062  
Regd. Office: 201, 'Devavrata', Sector - 17,  
Vashi, Navi Mumbai - 400 703  
Corp. Office: Strides House,  
Bannerghatta Road, Bangalore - 560076

**PR Consultancy**

Fortuna PR  
K Srinivas Reddy: +91 90005 27213  
[srinivas@fortunapr.com](mailto:srinivas@fortunapr.com)

K Priya: +91 95354 25418  
[priya@fortunapr.com](mailto:priya@fortunapr.com)